Published in Gastric Cancer on January 01, 2006
Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case. World J Surg Oncol (2010) 0.88
Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports. Cases J (2008) 0.83
Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case. Surg Today (2012) 0.79
Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy. Sci Rep (2015) 0.76
Pathological complete response and long-term survival in a very elderly patient after neoadjuvant chemotherapy for locally advanced, unresectable gastric cancer. Case Rep Oncol Med (2014) 0.75
Interstitial lung disease caused by TS-1: a case of long-term drug retention as a fatal adverse reaction. J Korean Surg Soc (2011) 0.75
Current Development of Anti-Cancer Drug S-1. J Clin Diagn Res (2016) 0.75
Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer (1998) 16.63
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs (1996) 5.45
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer (1998) 3.81
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology (2000) 3.50
Japanese classification of gastric carcinoma--2nd English edition--response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer (2001) 2.19
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol (2000) 1.17
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer (2003) 1.14
Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park) (1999) 1.00
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case. Oncology (2001) 0.94
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer (2003) 0.90
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer (2003) 0.79
[A case report of advanced cardiac cancer showing a complete response to TS-1 as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho (2004) 0.79
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer (2003) 0.75
[A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP therapy]. Gan To Kagaku Ryoho (2003) 0.75
Current topics of S-1 at the 74th Japanese Gastric Cancer Congress. Gastric Cancer (2003) 0.75
Differential expression of ribosomal proteins in human normal and neoplastic colorectum. J Histochem Cytochem (2003) 1.36
Lymphoma as a cause of isolated oculomotor nerve palsy. J Clin Neurosci (2011) 1.23
Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer. Cancer Lett (2003) 1.08
Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol (2004) 0.99
Expression of ATP1AL1, a non-gastric proton pump, in human colorectum. Jpn J Physiol (2002) 0.88
Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett (2006) 0.87
Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol (2008) 0.86
Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach. Cancer Sci (2013) 0.84
Primary abscess of the omentum: report of a case. Surg Today (2004) 0.84
Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature. Ann Surg Oncol (2014) 0.79
Churg-Strauss syndrome presenting as myositis following unaccustomed exercise. J Clin Neurosci (2009) 0.79
Distinct Cytoplasmic Expression of KL-6 Mucin in Chromophobe Renal Cell Carcinoma: A Comparative Immunohistochemical Study with Other Renal Epithelial Cell Tumors. Acta Histochem Cytochem (2012) 0.77
Up-regulation of Kv7.1 channels in thromboxane A2-induced colonic cancer cell proliferation. Pflugers Arch (2013) 0.75
JC virus inclusions in progressive multifocal leukoencephalopathy: scaffolding promyelocytic leukemia nuclear bodies grow with cell cycle transition through an S-to-G2-like state in enlarging oligodendrocyte nuclei. J Neuropathol Exp Neurol (2014) 0.75
Significant deposition of wild type transthyretin-derived amyloid in the gastrointestinal tract of aged individuals. Amyloid (2009) 0.75
Linear calcification in the cortico-medullary junction of the kidney. Intern Med (2008) 0.75
Methylation of Tumor Suppressor Genes in Autoimmune Pancreatitis. Pancreas (2017) 0.75
Endomyocardial biopsy in a patient with hemorrhagic pheochromocytoma presenting as inverted Takotsubo cardiomyopathy. Heart Vessels (2012) 0.75
Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer. Oncol Rep (2005) 0.75
Pancreatic nonfunctioning neuroendocrine tumor with the main pancreatic duct obstruction presenting as excessive hyperglycemia: a case report and review of the literature. Pancreas (2012) 0.75
[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. Gan To Kagaku Ryoho (2010) 0.75